BRIEF-TapImmune announces phase 2 ovarian cancer trial study with Astrazeneca
April 21, 2016 at 10:44 AM EDT
* TapImmune announces phase 2 ovarian cancer trial study with Astrazeneca/Medimmune and Sloan Kettering Cancer Institute
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.